• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.

作者信息

Yeung Jensen, Vender Ron, Turchin Irina, Shukla Rahul, Maari Catherine, Hong Chih-Ho, Barakat Maxime, Lansang Perla

机构信息

Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada.

Department of Medicine, Division of Dermatology, McMaster University, Hamilton, Ontario, Canada; Dermatrials Research Inc, Hamilton, Ontario, Canada.

出版信息

J Am Acad Dermatol. 2021 Apr;84(4):1169-1171. doi: 10.1016/j.jaad.2020.11.013. Epub 2020 Nov 19.

DOI:10.1016/j.jaad.2020.11.013
PMID:33221464
Abstract
摘要

相似文献

1
Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.布罗达单抗在先前使用白细胞介素-17A抑制剂治疗失败的中重度银屑病患者中取得成功。
J Am Acad Dermatol. 2021 Apr;84(4):1169-1171. doi: 10.1016/j.jaad.2020.11.013. Epub 2020 Nov 19.
2
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.在先前的抗白细胞介素17A疗法失败的患者中，使用布罗达单抗治疗中度至重度银屑病。
J Am Acad Dermatol. 2019 Sep;81(3):857-859. doi: 10.1016/j.jaad.2019.05.007. Epub 2019 May 10.
3
IL-17 inhibitors for psoriasis.用于治疗银屑病的白细胞介素-17抑制剂
Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.
4
Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.一名患有严重银屑病的患者在使用司库奇尤单抗后发生湿疹，成功转换为使用布罗达单抗治疗。
Eur J Dermatol. 2020 Dec 1;30(6):732-734. doi: 10.1684/ejd.2020.3904.
5
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.IL-17 拮抗剂的成功同类内转换：一项多中心、多国回顾性研究。
Arch Dermatol Res. 2019 Jul;311(5):421-424. doi: 10.1007/s00403-019-01907-y. Epub 2019 Mar 16.
6
Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study.白细胞介素-17抑制剂治疗红皮病型银屑病患者的临床疗效和安全性：一项回顾性队列、三中心研究
Am J Clin Dermatol. 2024 Sep;25(5):857-859. doi: 10.1007/s40257-024-00873-0. Epub 2024 Jul 5.
7
A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.抗白细胞介素-17A单克隆抗体司库奇尤单抗治疗中重度斑块状银屑病的综述
Skin Therapy Lett. 2016 Nov;21(6):1-6.
8
Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.接受比美吉珠单抗治疗后斑块状银屑病迅速缓解。
J Drugs Dermatol. 2024 Aug 1;23(8):694-696. doi: 10.36849/JDD.8381.
9
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study.布罗达单抗在既往生物治疗失败后的中重度斑块状银屑病中的疗效：一项4期、多中心、开放标签研究。
J Am Acad Dermatol. 2024 Jun;90(6):1254-1256. doi: 10.1016/j.jaad.2024.01.025. Epub 2024 Jan 28.
10
Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients.在器官移植患者中，使用抗IL - 17A治疗银屑病不一定是禁忌的。
Eur J Dermatol. 2020 Jun 1;30(3):311-313. doi: 10.1684/ejd.2020.3776.

引用本文的文献

1
Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning.用于中重度银屑病的布罗达单抗：疗效、安全性及临床定位的全面综述
Biologics. 2025 Jul 15;19:415-422. doi: 10.2147/BTT.S532526. eCollection 2025.
2
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.布罗达单抗治疗银屑病的疗效及治疗失败的危险因素：一项事后分析综述
Dermatol Ther (Heidelb). 2024 Oct;14(10):2709-2726. doi: 10.1007/s13555-024-01264-3. Epub 2024 Sep 12.
3
Suppression of TCF4 promotes a ZC3H12A-mediated self-sustaining inflammatory feedback cycle involving IL-17RA/IL-17RE epidermal signaling.
TCF4的抑制促进了一个由ZC3H12A介导的、涉及IL-17RA/IL-17RE表皮信号的自我维持性炎症反馈循环。
JCI Insight. 2024 Mar 12;9(8):e172764. doi: 10.1172/jci.insight.172764.
4
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.布罗达单抗治疗中重度银屑病：专家德尔菲共识声明
J Clin Med. 2023 May 18;12(10):3545. doi: 10.3390/jcm12103545.
5
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.布罗达单抗在难治性银屑病中新兴治疗作用的叙述性综述
Dermatol Ther (Heidelb). 2022 Jun;12(6):1289-1302. doi: 10.1007/s13555-022-00746-6. Epub 2022 Jun 7.
6
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis.药物基因组学：生物制剂和小分子药物在银屑病治疗中的最新进展。
Genes (Basel). 2021 Sep 10;12(9):1398. doi: 10.3390/genes12091398.
7
Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.多种白细胞介素 (IL)-17 家族细胞因子通过白细胞介素-17 受体 A 发出信号，驱动银屑病相关炎症途径。
Br J Dermatol. 2021 Sep;185(3):585-594. doi: 10.1111/bjd.20090. Epub 2021 May 31.